Guest guest Posted December 24, 2010 Report Posted December 24, 2010 It's an interesting conundrum. HPV genotyping is not available outside of research settings currently. Planned Parenthood gives the vaccine to girls & women regardless of whether they've had any abnormal Pap or not. They figure it might protect them, and insurance pays for it if they're under 26. As for boys, the CDC still has not changed their recommendation from 'permissive' to 'routine' for boys receiving it, meaning MD's can give it but it's not considered 'required' and hence insurers are not required to pay for it for boys. Not yet, anyway. THis coming spring the CDC's ACIP will meet to decide whether or not to change the recommendation for boys: and some of us will be there to urge them to do so. ~ > > > > > > > Subject: NATAP: FDA Approves GARDASIL for Anal Cancer > > > > > > > > > > > > Dec. 22, 2010 > > > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL® > > > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL® > > > > > > GARDASIL now Approved for Prevention of Anal Cancer and AIN > > > > > > WHITEHOUSE STATION, N.J., Dec. 22, 2010 - Merck, known as MSD > outside the United States and Canada, announced today that the U.S. Food > and Drug Administration (FDA) has approved GARDASIL® [Human > Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, > Recombinant] for the prevention of anal cancer caused by human > papillomavirus (HPV) types 16 and 18 and for the prevention of anal > intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and > precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and > females 9 through 26 years of age. > > > > > > " We are pleased that with this new indication for GARDASIL against > HPV-related anal cancer and disease, both males and females can be > protected against cancer, which further reinforces the importance of > vaccinating both genders, " said M. Haupt, M.D., MPH, executive > director, Merck Research Laboratories. " GARDASIL is the only HPV vaccine > available for use in both males and females, and the only one indicated > to help prevent cervical, vaginal, vulvar and anal cancers and > pre-cancers, as well as genital warts, caused by certain types of HPV. " > > > > > > In the United States, an estimated 75 to 80 percent of males and > females will be infected with HPV in their lifetime. For most, HPV will > clear on its own. However, for those who don't clear certain types, HPV > can cause cervical, vaginal and vulvar cancers in women and anal cancer > and genital warts in men and women. There is no way to predict who will > or won't clear the virus. > > > > > > GARDASIL helps protect against the four types of HPV, specifically > types 6, 11, 16, and 18, that cause the most disease. It is estimated > that HPV types 16 and 18 account for approximately 80 percent of anal > cancers, 75 percent of cervical cancers, 70 percent of vaginal cancers > and 40 to 50 percent of vulvar cancers. HPV types 6 and 11 cause > approximately 90 percent of all genital warts cases. > > > > > > Anal cancer affects both men and women, with approximately 60 > percent of cases occurring in women. According to the American Cancer > Society, it is estimated that approximately 2,000 men and more than > 3,000 women will have been diagnosed with anal cancer in 2010. There is > no standardized screening recommended for the general population for > anal cancer and many people are diagnosed when the disease is more > advanced. > > > > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, > and 18) Vaccine, Recombinant] was approved in the United States in 2006 > and is also indicated for use in girls and young women 9 through 26 > years of age for the prevention of cervical, vulvar and vaginal cancers > caused by HPV types 16 and 18; genital warts (condylomata acuminata) > caused by HPV types 6 and 11; and precancerous or dysplastic lesions > caused by HPV types 6, 11, 16 and 18. GARDASIL is also approved in the > U.S. for use in boys and men ages 9 through 26 years of age for the > prevention of genital warts caused by HPV types 6 and 11. > > > > > > Important information about GARDASIL > > > GARDASIL does not eliminate the necessity for women to continue to > undergo recommended cervical cancer screening. > > > > > > Recipients of GARDASIL should not discontinue anal cancer screening > if it has been recommended by a health care provider. > > > > > > GARDASIL has not been demonstrated to provide protection against > diseases from vaccine and non-vaccine HPV types to which a person has > previously been exposed through sexual activity. > > > > > > GARDASIL is not intended to be used for treatment of active external > genital lesions; cervical, vulvar, vaginal, and anal cancers; cervical > intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal > intraepithelial neoplasia, or anal intraepithelial neoplasia. > > > > > > GARDASIL has not been demonstrated to protect against disease due to > HPV types not contained in the vaccine. > > > > > > Not all vulvar, vaginal, and anal cancers are caused by HPV, and > GARDASIL protects only against those vulvar, vaginal, and anal cancers > caused by HPV 16 and 18. > > > > > > Select safety information > > > GARDASIL is contraindicated in individuals with hypersensitivity, > including severe allergic reactions to yeast, or after a previous dose > of GARDASIL. > > > > > > Because vaccinees may develop syncope, sometimes resulting in > falling with injury, observation for 15 minutes after administration is > recommended. Syncope, sometimes associated with tonic-clonic movements > and other seizure-like activity, has been reported following vaccination > with GARDASIL. When syncope is associated with tonic-clonic movements, > the activity is usually transient and typically responds to restoring > cerebral perfusion. > > > > > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, > and 18) Vaccine, Recombinant] is not recommended for use in pregnant > women. > > > > > > The most common adverse reaction was headache. Common adverse > reactions that were observed among recipients of GARDASIL at a frequency > of at least 1.0 percent and greater than placebo were: fever, nausea, > dizziness; and injection-site pain, swelling, erythema, pruritus and > bruising. > > > > > > Dosage and administration for GARDASIL > > > GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. > GARDASIL should be administered in three separate intramuscular > injections in the deltoid region of the upper arm or in the higher > anterolateral area of the thigh. The following dosage schedule is > recommended: First dose at elected date, second dose two months after > the first dose and the third dose six months after the first dose. > > > > > > GARDASIL is approved in 121 countries > > > GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) > Vaccine, Recombinant] (sold in some countries as SILGARD®) has been > approved in 121 countries, and additional applications are currently > under review with regulatory agencies in many more countries around the > world. > > > > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.